• / Free eNewsletters & Magazine
  • / My Account
Home>Phosphagenics' A$19.3 million Capital Raising

Related Content

  1. Videos
  2. Articles
  1. Moats Widen for Railroads, Luxury Goods, and More

    Improved efficiencies, brand pricing power, and sufficient capital levels are some of the reasons behind these equity groups' higher moat ratings.

  2. Fuss: Time for Caution and Selectivity in Bonds

    Relative to history and expectations, bonds are overpriced in general, says Loomis Sayles Bond manager Dan Fuss, who is taking a selective approach with caution toward credit risk.

  3. Fuss' Picks for Currency Exposure

    On the currency front, the Loomis Sayles Bond manager likes New Zealand , Canada, and Norway, but is more cautious about some emerging markets, including Brazil and Mexico.

  4. Diving Into Economic Moats

    We recently launched a dedicated economic moat section in our Premium Stock Analyst Reports.

Phosphagenics' A$19.3 million Capital Raising

Phosphagenics' A$19.3 million Capital Raising

07/11/2014

- Includes A$3 million Share Purchase Plan

- Upcoming opioid pain patch trials fully funded

MELBOURNE, Australia, July 11, 2014 /PRNewswire/ -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$19.3 million via a placement of A$16.3 million to institutional investors in Europe, the U.S., Asia and Australia and A$3 million from a share purchase plan (SPP) to be offered to existing shareholders.  The placement of A$16.3 million will be made in two tranches.

"This capital raising positions us strongly to fulfil our commercialisation objectives and fully funds our scheduled TPM®/opioid clinical trial programs.  The capital raised is earmarked for our pivotal TPM®/Oxymorphone Phase 2 clinical trial in the USA scheduled for the first half of 2015 and our upcoming TPM®/Oxycodone Phase 2 trial in Australia," said CEO, Harry Rosen.

"The capital raising comes at a time when the Company is focusing on exploiting the commercialization of several of its lead programs.  We have recently strengthened our business development capacity in the U.S. to assist in this process.  While we have unquestionably shown that our technology provides enhanced delivery solutions across a wide range of products, we now need to translate this to commercial outcomes," said Harry Rosen.

The completion of this capital raising and the investment by new and existing institutional shareholders is a strong endorsement of the TPM® technology and commercial prospects of Phosphagenics.

The institutional placement is for initially 153,000,000 shares at 8 cents per share. This represents a discount of 11% to the last sale price of 9 cents.  A placement of a further 51,000,000 shares at the same price will be subject to shareholders' approval at a General Meeting to be held on or around August 25, 2014.

The lead manager of the placement was Bell Potter Securities Ltd, assisted by Taylor Collison Ltd. as co-manager for Australian institutions. The Company received widespread support from local and overseas institutional investors, the majority of which were healthcare specific investment funds, which responded positively to the Company's technology and strategic plans. Several of Phosphagenics existing institutional holders also took allocations in this placement.

blog comments powered by Disqus
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.